A device for autonomously adjusting a long acting insulin medicament dosage in a prescribed insulin regimen for a subject, wherein the device comprises one or more processors and a memory, the memory comprising:
- a first data structure that includes the prescribed insulin regimen including a basal insulin medicament dosage regimen, wherein the basal insulin medicament dosage regimen specifies the long acting insulin medicament dosage and wherein the first data structure further comprises:
- (i) a target fasting blood glucose level,
- (ii) a minimum target fasting blood glucose level, and
- (iii) a maximum target fasting blood glucose level, an indication as to when the subject is to inject, and
- instructions that, when executed by the one or more processors, perform a method of:
- obtaining a first data set, the first data set comprising a plurality of glucose measurements of the subject taken over a time course and, for each respective glucose measurement in the plurality of glucose measurements, a corresponding timestamp representing when in the time course the respective glucose measurement was made;
- obtaining a second data set from one or more insulin pens used by the subject to apply the prescribed insulin regimen, the second data set comprising a plurality of insulin medicament records over the time course, each insulin medicament record in the plurality of medicament records comprising:
- (i) a respective insulin medicament injection event representing an insulin medicament injection into the subject using a respective insulin pen in the one or more insulin pens, and
- (ii) a corresponding electronic timestamp that is automatically generated by the respective insulin pen upon occurrence of the respective insulin medicament injection event;
- updating a first glycaemic risk measure, wherein the first glycaemic risk measure is:
- (i) a total glucose level variability observed across the plurality of glucose measurements,
- (ii) a variability in a plurality of fasting glucose levels calculated from the plurality of glucose measurements, or
- (iii) a minimum glucose measurement observed in the plurality of glucose measurements;
- computing a fasting blood glucose target function that is based upon at least the first glycaemic risk measure thereby obtaining an updated target fasting blood glucose level that is between the minimum target fasting blood glucose level and the maximum target fasting blood glucose level;
- and
- adjusting the long acting insulin medicament dosage based upon the updated target fasting blood glucose level, wherein
- the first data structure further comprises an indication as to when the subject is to inject the long acting insulin medicament dosage, and the method further comprises:
- the fasting blood glucose target function is based upon at least the first glycaemic risk measure and a second glycaemic risk measure, wherein the first glycaemic risk measure and the second glycaemic risk measure are each independently:
- (i) the total glucose level variability observed across the plurality of glucose measurements,
- (ii) the variability in the plurality of fasting glucose levels calculated from the plurality of glucose measurements,
- (iii) the minimum glucose measurement observed in the plurality of glucose measurements,
- (iv) a rate of change in an insulin sensitivity factor calculated using the plurality of glucose measurements and the second data set, or
- (v) a basal adherence score over the time course that is computed by dividing (a) a number of insulin medicament injection events that were taken by the subject when dictated by the basal insulin medicament dosage regimen by (b) a total number of basal insulin medicament injection events dictated by the basal insulin medicament dosage regimen in the time course.